The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
Open accessAbstract
Natural killer (NK) cells are potent cytotoxic effector cells for cancer therapy and potentially for severe viral infections. However, there are technical challenges to obtain sufficient numbers of functionally active NK cells from a patient's blood since they represent only 10% of the lymphocytes and are often dysfunctional. The alternative is to obtain cells from a healthy donor, which requires depletion of the allogeneic T cells to prevent graft-versus-host reactions. Cytotoxic cell lines have been established from patients with clonal NK-cell lymphoma. Those cells can be expanded in culture in the presence of IL-2. Except for the NK-92 cell line, though, none of the other six known NK cell lines has consistently and reproducibly shown high antitumor cytotoxicity. Only NK-92 cells can easily be genetically manipulated to recognize specific tumor antigens or to augment monoclonal antibody activity through antibody-dependent cellular cytotoxicity. NK-92 is also the only cell line product that has been infused into patients with advanced cancer with clinical benefit and minimal side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“The rationale for a treatment that combines mAb treatment with haNK infusions is based on the number of retrospective studies demonstrating an improved overall survival benefit in patients expressing the high-affinity FcγRIIIa receptor upon treatment with mAbs, such as Rituxan® (lymphoma), Herceptin® (breast cancer),…”
BackgroundGong, J.-H., Maki, G., & Klingemann, H.-G. (1994) · PubMed · Cited by 723
Self-citationMembrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030264 · Cited by 683
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Zhang, W., Gordon, M., Schultheis, A. M., Yang, D. Y., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 482
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 467
Self-citationChu, J., Deng, Y., Benson, D. M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., et al. (2014) · Leukemia · doi:10.1038/leu.2013.279 · Cited by 439
Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., & Klingemann, H. (2008) · Cytotherapy · doi:10.1080/14653240802301872 · Cited by 434
Self-citationKnorr, D. A., Ni, Z., Hermanson, D., Hexum, M. K., Bendzick, L., Cooper, L. J. N., Lee, D. A., & Kaufman, D. S. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0084 · Cited by 415
Schönfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M., Nowakowska, P., Bönig, H., Köhl, U., Kloess, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.219 · Cited by 348
Self-citationCharacterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia.
Robertson, M. J., Cochran, K., Cameron, C. A., Le, J. M., Tantravahi, R. V., & Ritz, J. (1996) · PubMed · Cited by 343
Han, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J. B., Victor, A., Meisen, W. H., Kim, S.-H., Grandi, P., et al. (2015) · Scientific Reports · doi:10.1038/srep11483 · Cited by 340
Furusato, B., Mohamed, A., Uhlén, M., & Rhim, J. S. (2010) · Pathology International · doi:10.1111/j.1440-1827.2010.02548.x · Cited by 290
Are natural killer cells superior CAR drivers?
Klingemann, H. (2014) · OncoImmunology · doi:10.4161/onci.28147 · Cited by 270
Self-citationFactors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92
Maki, G., Klingemann, H.-G., Martinson, J. A., & Tam, Y. K. (2001) · Journal of Hematotherapy & Stem Cell Research · doi:10.1089/152581601750288975 · Cited by 262
Self-citationShah, N. N., Baird, K., Delbrook, C. P., Fleisher, T. A., Kohler, M. E., Rampertaap, S., Lemberg, K., Hurley, C. K., Kleiner, D. E., Merchant, M. S., et al. (2015) · Blood · doi:10.1182/blood-2014-07-592881 · Cited by 238
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
Childs, R. W., & Carlsten, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4506 · Cited by 236
Human Embryonic Stem Cell-Derived NK Cells Acquire Functional Receptors and Cytolytic Activity
Woll, P. S., Martin, C. H., Miller, J. S., & Kaufman, D. S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5095 · Cited by 233
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
Lapteva, N., Durett, A. G., Sun, J., Rollins, L. A., Huye, L. L., Fang, J., Dandekar, V., Mei, Z., Jackson, K., Vera, J., et al. (2012) · Cytotherapy · doi:10.3109/14653249.2012.700767 · Cited by 216
Müller, T., Uherek, C., Maki, G., Chow, K. U., Schimpf, A., Klingemann, H.-G., Tonn, T., & Wels, W. S. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0383-3 · Cited by 212
Self-citationBoissel, L., Betancur, M., Lu, W., Krause, D., Van Etten, R., Wels, W., & Klingemann, H. (2013) · OncoImmunology · doi:10.4161/onci.26527 · Cited by 194
Self-citationYagita, M., Huang, C., Umehara, H., Matsuo, Y., Tabata, R., Miyake, M., Konaka, Y., & Takatsuki, K. (2000) · Leukemia · doi:10.1038/sj.leu.2401769 · Cited by 186
Sahm, C., Schönfeld, K., & Wels, W. S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1212-x · Cited by 186
CXCR2‐mediated tumor‐associated neutrophil recruitment is regulated by IFN‐β
Jablonska, J., Wu, C. ‐., Andzinski, L., Leschner, S., & Weiss, S. (2014) · International Journal of Cancer · doi:10.1002/ijc.28551 · Cited by 179
MacFarlane, A. W., Jillab, M., Plimack, E. R., Hudes, G. R., Uzzo, R. G., Litwin, S., Dulaimi, E., Al-Saleem, T., & Campbell, K. S. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0133 · Cited by 177
Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
Hermanson, D. L., & Kaufman, D. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00195 · Cited by 172
Antileukemia activity of a natural killer cell line against human leukemias.
Yan, Y., Steinherz, P. G., Klingemann, H., Dennig, D., Childs, B. H., McGuirk, J. P., & O’Reilly, R. J. (1998) · PubMed · Cited by 167
Self-citationBoissel, L., Betancur, M., Wels, W. S., Tuncer, H., & Klingemann, H. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.024 · Cited by 166
Self-citationSomanchi, S. S., Somanchi, A., Cooper, L. J. N., & Lee, D. A. (2012) · Blood · doi:10.1182/blood-2011-11-389924 · Cited by 135
Tam, Y. K., Miyagawa, B., HO, V. C., & Klingemann, H.-G. (1999) · Journal of Hematotherapy · doi:10.1089/106161299320316 · Cited by 133
Self-citationCombination Strategies to Enhance Antitumor ADCC
Kohrt, H. E. K., Houot, R., Marabelle, A., Cho, H. J., Osman, K., Goldstein, M. J., Levy, R., & Brody, J. (2012) · Immunotherapy · doi:10.2217/imt.12.38 · Cited by 111
Taylor, R. J., Chan, S., Wood, A., Voskens, C., Wolf, J. S., Lin, W., Chapoval, A. I., Schulze, D. H., Tian, G., & Strome, S. E. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0613-3 · Cited by 103
Replicative potential of human natural killer cells
Fujisaki, H., Kakuda, H., Imai, C., Mullighan, C. G., & Campana, D. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07667.x · Cited by 103
Tsuchiyama, J., Yoshino, T., Mori, M., et al. (1998) · Blood · doi:10.1182/blood.v92.4.1374 · Cited by 97
Swift, B. E., Williams, B. A., Kosaka, Y., Wang, X.-H., Medin, J. A., Viswanathan, S., Martínez‐López, J., & Keating, A. (2012) · Haematologica · doi:10.3324/haematol.2011.054254 · Cited by 74
Retargeting NK‐92 for anti‐melanoma activity by a TCR‐like single‐domain antibody
Zhang, G., Liu, R., Zhu, X., Wang, L., Ma, J., Han, H., Wang, X., Zhang, G., He, W. Z., Wang, W., et al. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.45 · Cited by 70
Bock, A. M., Knorr, D. A., & Kaufman, D. S. (2013) · Journal of Visualized Experiments · doi:10.3791/50337 · Cited by 55
Seidel, D., Shibina, A., Siebert, N., Wels, W. S., Reynolds, C. P., Huebener, N., & Lode, H. N. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1669-5 · Cited by 48
Ames, E., Hallett, W. H. D., & Murphy, W. J. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2008.03818.x · Cited by 48
Cheng, M., Ma, J., Chen, Y., Zhang, J., Zhao, W., Zhang, J., Wei, H., Ling, B., Sun, R., & Tian, Z. (2011) · Cell Transplantation · doi:10.3727/096368911x580536 · Cited by 47
Son, C., Keum, J.-H., Yang, K., Nam, J., Kim, M., Kim, S., Kang, C., Oh, S., Kim, C., Park, Y.-S., et al. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-49 · Cited by 41
Cited by
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
Li, Y., Hermanson, D. L., Moriarity, B. S., & Kaufman, D. S. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.06.002 · Cited by 981
Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma
Zhu, L., Kalimuthu, S., Gangadaran, P., Oh, J. M., Lee, H. W., Baek, S. H., Jeong, S. Y., Lee, S.-W., Lee, J., & Ahn, B.-C. (2017) · Theranostics · doi:10.7150/thno.18752 · Cited by 471
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Hu, W., Wang, G., Huang, D., Sui, M., & Xu, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01205 · Cited by 398
Zhang, C., Oberoi, P., Oelsner, S., Waldmann, A., Lindner, A., Tonn, T., & Wels, W. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00533 · Cited by 306
Metadata
- Authors
- Klingemann, H., Boissel, L., & Toneguzzo, F.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2016-03-14
- Volume
- 7
- Pages
- 91-91
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2298503769
- Cited by
- 414
- References
- 45
- FWCI
- 20.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.